Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
Follow OMER
Omeros Corporation (OMER) Piotroski F-score
Omeros Corporation's Piotroski F-score for fiscal 2018 is 1 out of 9: 1 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2017.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2020 | 2 | (2.00) |
| FY2019 | 4 | 3.00 |
| FY2018 | 1 | (4.00) |
| FY2017 | 5 | (1.00) |
| FY2016 | 6 | — |
How fiscal 2018’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (119.43%) | (58.26%) | Fail | 0 |
| Positive operating cash flow | (103.74m) | (36.23m) | Fail | 0 |
| Rising return on assets | (119.43%) | (58.26%) | Fail | 0 |
| Cash flow above net income | 23.02m | 17.25m | Pass | 1 |
| Falling long-term leverage | 1.40 | 0.91 | Fail | 0 |
| Rising current ratio | 2.41 | 4.12 | Fail | 0 |
| No new shares issued | 48,583,000 | 45,539,000 | Fail | 0 |
| Rising gross margin | 98.29% | 98.34% | Fail | 0 |
| Rising asset turnover | 0.28 | 0.71 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 1 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ANAB AnaptysBio, Inc. compare | 5 |
| NKTR Nektar Therapeutics compare | 3 |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | 3 |
| INBX Inhibrx Biosciences, Inc. compare | 2 |
| OMER Omeros Corporation | 2 |
| GHRS GH Research PLC compare | — |
| TYRA Tyra Biosciences, Inc. compare | — |
| ORIC Oric Pharmaceuticals, Inc. compare | — |
| RAPP Rapport Therapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover